PharVision Advisers’s Sempra SRE Stock Holding History

PharVision Advisers’s Portfolio SRE Stock Details SRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,437	Closed	-$245K	–	420
2025 Q1	$245K	Sell	3,437 -945	-22%	-$73.6K	0.34%	142
2024 Q4	$384K	Buy	+4,382	New	+$383K	0.33%	88

Other funds holding SRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Newport Trust Company Washington, District of Columbia $40.7B AUM 24.62% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

PharVision Advisers's SRE Position: Q2 2025 in Review

PharVision Advisers sold out of Sempra (SRE) in Q2 2025, closing a stake of 3,437 shares — an estimated $245K sold.

PharVision Advisers first reported a position in SRE in Q4 2024 and held it in 2 quarters. The position peaked at $384K in Q4 2024. 1,121 funds tracked by Wall St. Rank hold SRE as of Q2 2025.

PharVision Advisers reported no remaining Sempra position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 3,437 Sempra shares in Q2 2025, an estimated $245K.
PharVision Advisers first reported a position in Sempra in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Sempra position peaked at $384K in Q4 2024.
1,121 funds tracked by Wall St. Rank held Sempra as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.